Research Update
Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder
Anna Vinter, MD. Dr. Vinter has no financial relationships with companies related to this material.
Items Tagged with 'liraglutide'
ARTICLES
CLINICAL UPDATE
Liraglutide: A Generic Option for Weight Gain
Edmund S. Higgins, MD. Affiliate Associate Professor, Psychiatry and Behavioral Sciences, Medical University of South Carolina.
Dr. Higgins reports stock ownership in Bristol-Myers-Squibb and Johnson & Johnson. Dr. Aiken has reviewed this educational activity and determined that there is no commercial bias as a result of this financial relationship.
Clinical Update
GLP-1 Receptor Agonists in Addiction Treatment: The Next Big Thing or Just Hype?
Michael Weaver, MD, DFASAM. Professor and Medical Director, Center for Neurobehavioral Research on Addiction at the University of Texas Medical School, Houston, TX.
Noah Capurso, MD, MHS. Assistant Medical Director, Addiction Services Division, Connecticut Valley Hospital; Associate Clinical Professor of Psychiatry, Yale University; Editor-in-Chief, The Carlat Addiction Treatment Report.
Drs. Weaver and Capurso have no financial relationships with companies related to this material.
Clinical Update
New Weight Loss Drugs in Psychiatry
Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.
David Liebers, MD. Psychiatry resident at NYU Langone, Department of Psychiatry.
Drs. Aiken and Liebers have no financial relationships with companies related to this material.
Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain
Farah Khorassani, PharmD. Clinical Assistant
Professor of Pharmacy Practice, St. John’s University, Queens, NY.
Dr. Khorassani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Read More
Weight Gain and Metabolic Side Effects
Stephen Marder, MD
Daniel X. Freedman Professor of Psychiatry. Vice Chair for Education, Semel Institute for Neuroscience at UCLA. Director, VA VISN 22 Mental Illness Research, Education, and Clinical Center, San Diego, CA.
Dr. Marder has disclosed no relevant financial or other interests in any commercial companies pertaining to educational activity.
Carlat Total Access Subscriptions: Get access to every article on the website.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?t=1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
Recommended
